# US 8,785,129 B2 · Method and probe set for detecting cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,129 B2
- Document ID: US8785129B2
- Status: Granted
- Kind: B2
- Application number: 13/893,067
- Filed: 2013-05-13
- Published: 2013-11-28
- Granted: 2014-07-22
- Earliest claimed: 1999-03-05
- Assignees: Mayo Foundation for Medical Education and Research; Abbott Molecular Inc.
- Applicants: Mayo Foundation for Medical Education and Research; Abbott Molecular Inc.
- Inventors: Kevin C. Halling; Robert B. Jenkins; Walter King; Irina A. Sokolova; Steven A. Seelig
- Web page: https://patentgrep.com/patent/US8785129B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6841: In situ hybridisation
- C12Q 2537/143: Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
- C12Q 2537/16: Assays for determining copy number or wherein the copy number is of special importance
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.

## Claims

### Claim 1

A method of detecting aneusomic cells, said method comprising:
a) obtaining a kit comprising a set of chromosomal probes consisting of centromeric chromosomal probes to chromosomes 3, 7, and 17 or centromeric chromosomal probes to chromosomes 3, 7, and 17 and a locus-specific probe to 9p21;
b) hybridizing said set of chromosomal probes of said kit to a biological sample from a subject; and
c) detecting aneusomic cells by examining the hybridization pattern of said set of chromosomal probes in said biological sample.

### Claim 2 (depends on 1)

The method of claim 1, comprising selecting a plurality of cytologically abnormal cells from said biological sample and detecting aneusomic cells in said selected cells by examining the hybridization pattern of said set of chromosomal probes in each of said selected cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein cells are selected by nuclear morphology.

### Claim 4 (depends on 2)

The method of claim 2, wherein cells are selected by nuclear size.

### Claim 5 (depends on 2)

The method of claim 2, wherein cells are selected by nuclear shape.

### Claim 6 (depends on 1)

The method of claim 1, wherein said chromosomal probes are fluorescently labeled.

### Claim 7 (depends on 1)

The method of claim 1, wherein said biological sample is selected from the group consisting of urine, blood, cerebrospinal fluid, pleural fluid, sputum, peritoneal fluid, a bladder washing, oral washing, tissue sample, touch prep, and fine-needle aspirate.

### Claim 8

A method of performing fluorescence in situ hybridization, said method comprising:
a) hybridizing a set of chromosomal probes consisting of centromeric probes to chromosomes 3, 7, and 17 to a biological sample from a subject; and
b) detecting aneusomic cells by examining the hybridization pattern of said set of chromosomal probes in said biological sample.

### Claim 9 (depends on 8)

The method of claim 8, comprising selecting a plurality of cytologically abnormal cells from said biological sample and detecting aneusomic cells in said selected cells by examining the hybridization pattern of said set of chromosomal probes in each of said selected cells.

### Claim 10 (depends on 9)

The method of claim 9, wherein cells are selected by nuclear morphology.

### Claim 11 (depends on 9)

The method of claim 9, wherein cells are selected by nuclear size.

### Claim 12 (depends on 9)

The method of claim 9, wherein cells are selected by nuclear shape.

### Claim 13 (depends on 8)

The method of claim 8, wherein said chromosomal probes are fluorescently labeled.

### Claim 14 (depends on 8)

The method of claim 8, wherein said biological sample is selected from the group consisting of urine, blood, cerebrospinal fluid, pleural fluid, sputum, peritoneal fluid, a bladder washing, oral washing, tissue sample, touch prep, and fine-needle aspirate.